Embolic protection device company raises US$5million in series B financing for advanced device development and initiation of US clinical activities

297

Innovative Cardiovascular Solutions has announced today completion of an oversubscribed Series B round of financing totalling US$5M. The company is currently developing the Emblok embolic protection system, which is designed for use in transcatheter aortic valve implantation (TAVI) and other structural heart procedures where embolic protection is required. Proceeds will be used for device development and initiation of a 510(k) clinical study in the USA.   

A press release reports that the Emblok system is the world’s first and only embolic protection device designed to offer complete circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from liberated embolic debris. Additionally, the system features an integrated 4 r radiopaque pigtail catheter that provides the physician constant visualisation, while eliminating the need for unnecessary dye injections to verify positioning. The entire system is 11Fr and allows two devices (ie., embolic filter and pigtail catheter) to be deployed through a single femoral puncture site.

Azeem Latib (San Raffaele Hospital in Milan, Italy) says: “The Emblok system is intuitive and easy to use. It is the only system to provide full capture and protection from embolic material released during TAVI and has become a necessary addition in my left heart interventions.”

LEAVE A REPLY